UK's Creo Medical H1 revenue surges, loss narrows
UK's Creo Medical H1 revenue surges, loss narrows
Overview
UK medical device firm's H1-26 revenue rose 45% yr/yr, in line with management expectations
Underlying operating loss for H1-26 narrowed by over 25% to £4.9 mln
Company completed £5.5 mln equity placing and secured £2 mln convertible loan note in May 2026
Outlook
Creo Medical expects full-year revenue growth of 50% to 60%
Company says H2 revenue profile is supported by a strong order book and usual seasonality
Company expects proceeds from CME Stake Disposal to strengthen near-term balance sheet
Result Drivers
PROCEDURAL ADOPTION - Co said revenue growth was supported by increased adoption of its advanced energy platform and broader clinician engagement
COST CONTROL - Co attributed reduced operating costs to disciplined cost control and a simplified operating model
CLINICAL VALIDATION - Co said growing external clinical validation and key opinion leader presentations supported commercial adoption
Company press release: ID:nRSd8599Wa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Underlying EBIT on contops basis |
| -GBP 4.9 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Creo Medical Group PLC is GBp55.00, about 363.2% above its September 29 closing price of GBp11.88
Reuters Recommended Reads
Sept 29 - UK's Billington Holdings H1 profit jumps 70% on data centre demand
Sept 28 - Betting firms Flutter and Entain warn of hit from Brazil's online betting ban
Sept 28 - Tullow Oil swings to positive free cash flow as Ghana output, higher oil prices drive growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)